Abstract
Current guidelines recommend that percutaneous coronary intervention (PCI) should be restricted to the culprit vessel in ST elevation myocardial infarction (STEMI) patients with multi-vessel disease (MVD) and without cardiogenic shock. However, newer data suggests that performing complete revascularization (CR) in MVD patients may lead to better outcomes compared to intervention in the culprit vessel only. The aim of this meta-analysis is to examine the available data to determine if CR (using either angio- or fractional flow reserve guidance—FFR) following primary PCI in STEMI patients without cardiogenic shock impacts clinical outcomes. Meta-analysis was performed by conducting a literature search of PubMed from January 2004 to July 2017. Pooled estimates of outcomes, presented as odds ratios (OR) [95% confidence intervals], were generated using random-effect models. A total of 9 studies (3317 patients) were included. CR showed a significant MACE reduction (OR 0.49, 95% CI 0.36–0.66, p < 0.001); All-cause mortality (OR 0.69, 95% CI 0.48–0.98, p = 0.04) and repeat revascularization (OR 0.38, 95% CI 0.28–0.51, p < 0.001) at ≥ 12 months follow-up. The FFR-guiding CR group presented a MACE reduction (odds ratio 0.52, 95% CI 0.30–0.90, p = 0.02) due to a decrease of repeat revascularization (OR 0.41, 95% CI 0.21–0.80, p = 0.009). Overall, performing complete revascularization in STEMI patients showed a MACE reduction, all-cause death and repeat revascularization. Compared to culprit-only revascularization, treating multi-vessel disease in STEMI patients using FFR guidance is associated with decreased incidence of MACE, due to a decreased rate of revascularization.
Similar content being viewed by others
References
Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van ’t Hof AW, Suryapranata H (1999) Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341(19):1413–1419
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361(9351):13–20. Review
Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, Stone GW (2007 Jul) Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 28(14):1709–1716
Han YL, Wang B, Wang XZ, Li Y, Wang SL, Jing QM et al (2008) Comparative effects of percutaneous coronary intervention for infarct-related artery only or for both infarct- and non-infarct-related arteries in patients with ST-elevation myocardial infarction and multi-vessel disease. Chin Med J 121(23):2384–2387
Park DW, Clare RM, Schulte PJ, Pieper KS, Shaw LK, Califf RM, Ohman EM, Van de Werf F, Hirji S, Harrington RA, Armstrong PW, Granger CB, Jeong MH, Patel MR. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA 312(19):2019–2027. https://doi.org/10.1001/jama.2014.15095
Toma M, Buller CE, Westerhout CM, Fu Y, O’Neill WW, Holmes DR Jr, Hamm CW, Granger CB, Armstrong PW; APEX-AMI Investigators. (2010 Jul) Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J 31(14):1701–1707. https://doi.org/10.1093/eurheartj/ehq129
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Uva MS, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2015 Feb) 2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed) 68(2):144. https://doi.org/10.1016/j.rec.2014.12.006
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P (2017) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. https://doi.org/10.1093/eurheartj/ehx393
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting HH, O’Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey DE Jr, Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX (2016) 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients With ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 133(11):1135–1147. https://doi.org/10.1161/CIR.0000000000000336
Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PK. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate use criteria for coronary revascularization in patients with acute coronary syndromes: a report of the american college of cardiology appropriate use criteria task force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. J Nucl Cardiol 24(2):439–463. https://doi.org/10.1007/s12350-017-0780-8
Zir LM, Miller SW, Dinsmore RE, Gilbert JP, Harthorne JW (1976) Interobserver variability in coronary angiography. Circulation 53:627–632
Galbraith JE, Murphy ML, de Soyza N (1978) Coronary angiogram interpretation: interobserver variability. JAMA 240:2053–2056
Reiber JH, Serruys PW, Kooijman CJ, Wijns W, Slager CJ, Gerbrands JJ, Schuurbiers JC, den Boer A, Hugenholtz PG (1985 Feb) Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 71(2):280–288
Fleming RM, Kirkeeide RL, Smalling RW, Gould KL (1991) Patterns in visual interpretation of coronary arteriograms as detected by quantitative coronary arteriography. J Am Coll Cardiol 18(4):945–951
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF (2012) FAME 2 trial investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367(11):991–1001. https://doi.org/10.1056/NEJMoa1205361. Epub 2012 Aug 27. Erratum in: N Engl J Med. 2012 Nov;367(18):1768. Mobius-Winckler, Sven [corrected to Möbius-Winkler, Sven]
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012
Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F (2005) A simple hint to improve Robinson and Dickersin’s highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 34(1):224–225 author reply 225.
Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org
Review Manager (RevMan) [Computer program] (2014) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834
Biondi-Zoccai GGL, Abbate A, Agostoni P, Testa L, Burzotta F, Lotrionte M et al (2005) Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. Am Heart J 149(3):504–511
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ 343:d4002. https://doi.org/10.1136/bmj.d4002
Galvão Braga C, Cid-Álvarez AB, Redondo Diéguez A, Trillo-Nouche R, Álvarez Álvarez B, López Otero D, Ocaranza Sánchez R, Gestal Romaní S, González Ferreiro R, González-Juanatey JR (2016) Multivessel versus culprit-only percutaneous coronary intervention in ST-segment elevation acute myocardial infarction: analysis of an 8-year registry. Rev Esp Cardiol (Engl Ed). https://doi.org/10.1016/j.rec.2016.09.027
Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP (2015) Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 65:963–972
Hlinomaz O (2015) Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy: the PRAGUE 13 trial. Eur Heart J 36:825 Presented at: EuroPCR, May 19, 2015; Paris, France
Hlinomaz O, Groch L, Polokova L, Lehar F, Vekov T, Petkov R, Stojnev M, Griva M, Sitar J, Rezek M, Novak M, Semenka J, Penkov N (2015) Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. Prague-13 trial. Kardiol Rev Int Med 17(3):214–220
Ochala A, Smolka GA, Wojakowski W, Dudek D, Dziewierz A, Krolikowski Z (2004) The function of the left ventricle after complete multivessel one-stage percutaneous coronary intervention in patients with acute myocardial infarction. J Invasive Cardiol 16(12):699–702
Tarasov RS, Ganiukov VI, Popov VA, Shushpannikov PA, Barbarash OL, Barbarash LS (2013) Effect of the terms of complete revascularization on the outcomes of treatment of patients with ST segment elevation myocardial infarction and multivessel coronary artery disease. Angiologiia i Sosudistaia Khirurgiia 19(4):14–20
Dambrink J-HE, Debrauwere JP, Hof AWJ, van Ottervanger J-P, Gosselink ATM, Hoorntje JCA, Boer M-J de (2010) Suryapranata H. Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines? EuroIntervention 5:968–975
Krishnan SK, Riley RF, Hira RS, Lombardi WL (2017) Multivessel revascularization in shock and high-risk percutaneous coronary intervention. Interv Cardiol Clin 6(3):407–416. https://doi.org/10.1016/j.iccl.2017.03.009
Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L (2015) DANAMI-3—PRIMULTI investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 386:665–671
Ghani A, Dambrink JH, van ‘t Hof AW, Ottervanger JP, Gosselink AT, Hoorntje JC (2012) Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomised clinical trial. Neth Heart J 20:347–353
Politi L, Sgura F, Rossi R, Monopoli D, Guerri E, Leuzzi C, Bursi F, Sangiorgi GM, Modena MG (2010) A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart 96:662–667
Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, Hambrecht R, Angerås O, Richardt G, Omerovic E (2017) Compare-acute investigators. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. https://doi.org/10.1056/NEJMoa1701067
Di Mario C, Mara S, Flavio A, Imad S, Antonio M, Anna P, Emanuela P, Stefano DS, Angelo R, Stefania C, Anna F, Carmelo C, Antonio C, Monzini N, Bonardi MA (2004) Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) study. Int J Cardiovasc Intervent 6:128–133
Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG (2013) PRAMI investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 369:1115–1123
Bainey KR, Mehta SR, Lai T, Welsh RC (2014) Complete versus culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Am Heart J 167(1):1–14.e2. https://doi.org/10.1016/j.ahj.2013.09.018
El-Hayek GE, Gershlick AH, Hong MK, Casso Dominguez A, Banning A, Afshar AE, Herzog E, Tamis-Holland JE (2015) Meta-analysis of randomized controlled trials comparing multivessel versus culprit-only revascularization for patients with ST-segment elevation myocardial infarction and multivessel disease undergoing primary percutaneous coronary intervention. Am J Cardiol 115(11):1481–1486. https://doi.org/10.1016/j.amjcard.2015.02.046
Kowalewski M, Schulze V, Berti S, Waksman R, Kubica J, Kołodziejczak M, Buffon A, Suryapranata H, Gurbel PA, Kelm M, Pawliszak W, Anisimowicz L, Navarese EP. Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. Heart 2015 101(16):1309–1317. https://doi.org/10.1136/heartjnl-2014-307293
Tarantini G, D’Amico G, Brener SJ, Tellaroli P, Basile M, Schiavo A, Mojoli M, Fraccaro C, Marchese A, Musumeci G, Stone GW (2016) Survival after varying revascularization strategies in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: a pairwise and network meta-analysis. JACC Cardiovasc Interv 9(17):1765–1776. https://doi.org/10.1016/j.jcin.2016.06.012
Wang CH, Zhang SY, Jin XF (2017) Complete revascularization versus culprit-only revascularization in ST-segment elevation myocardial infarction and multivessel disease patients undergoing primary percutaneous coronary intervention: a meta-analysis and trial sequential analysis. Int J Cardiol 228:844–852. https://doi.org/10.1016/j.ijcard.2016.11.186
Bravo CA, Hirji SA, Bhatt DL, Kataria R, Faxon DP, Ohman EM, Anderson KL, Sidi AI, Sketch MH, Zarich SW, Osho AA, Gluud C, Kelbæk H, Engstrøm T, Høfsten DE, Brennan JM (2017) Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. Cochrane Database Syst Rev 5:CD011986. https://doi.org/10.1002/14651858.CD011986
Nguyen AV, Thanh LV, Kamel MG, Abdelrahman SAM, El-Mekawy M, Mokhtar MA, Ali AA, Hoang NNN, Vuong NL, Abd-Elhay FA, Omer OA, Mohamed AA, Hirayama K, Huy NT (2017) Optimal percutaneous coronary intervention in patients with ST-elevation myocardial infarction and multivessel disease: an updated, large-scale systematic review and meta-analysis. Int J Cardiol. 244:67–76. https://doi.org/10.1016/j.ijcard.2017.06.027
Gaffar R, Habib B, Filion KB, Reynier P, Eisenberg MJ (2017) Optimal timing of complete revascularization in acute coronary syndrome: a systematic review and meta-analysis. J Am Heart Assoc 6(4). pii: e005381. https://doi.org/10.1161/JAHA.116.005381
Zimmermann FM, Ferrara A, Johnson NP, van Nunen LX, Escaned J, Albertsson P, Erbel R, Legrand V, Gwon HC, Remkes WS, Stella PR, van Schaardenburgh P, Bech GJ, De Bruyne B, Pijls NH (2015) Deferral versus performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J36(45):3182–3188. https://doi.org/10.1093/eurheartj/ehv452
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’ t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF, FAME study investigators (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360(3):213–224. https://doi.org/10.1056/NEJMoa0807611
Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U (2017) CULPRIT-SHOCK investigators. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 377(25):2419–2432. https://doi.org/10.1056/NEJMoa1710261
Götberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, Olsson SE, Öhagen P, Olsson H, Omerovic E, Calais F, Lindroos P, Maeng M, Tödt T, Venetsanos D, James SK, Kåregren A, Nilsson M, Carlsson J, Hauer D, Jensen J, Karlsson AC, Panayi G, Erlinge D, Fröbert O (2017) iFR-SWEDEHEART investigators. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 376(11):1813–1823. https://doi.org/10.1056/NEJMoa1616540
Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Härle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J (2017) Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 376(19):1824–1834. https://doi.org/10.1056/NEJMoa1700445
Thim T, Götberg M, Fröbert O, Nijveldt R, van Royen N, Baptista SB, Koul S, Kellerth T, Bøtker HE, Terkelsen CJ, Christiansen EH, Jakobsen L, Kristensen SD, Maeng M (2017) Nonculprit stenosis evaluation using instantaneous wave-free ratio in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 10(24):2528–2535. https://doi.org/10.1016/j.jcin.2017.07.021
Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JH, Holm NR, Wijns W,FAVOR pilot trial study group (2016) Diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: the international multicenter FAVOR pilot study. JACC Cardiovasc Interv 9(19):2024–2035. https://doi.org/10.1016/j.jcin.2016.07.013
Kameyama T, Kubo T, Emori H, Ino Y, Matsuo Y, Yamano T et al (2016) TCT-542 usefulness of QFR measurement for non-culprit lesion of ACS patients. J Am Coll Cardiol 68(18):B219
Spitaleri G, Tebaldi M, Biscaglia S, Westra J, Brugaletta S, Erriquez A, Passarini G, Brieda A, Leone AM, Picchi A, Ielasi A, Girolamo DD, Trani C, Ferrari R, Reiber JHC, Valgimigli M, Sabatè M, Campo G (2018) Quantitative flow ratio identifies nonculprit coronary lesions requiring revascularization in patients With ST-segment-elevation myocardial infarction and multivessel disease. Circ Cardiovasc Interv 11(2):e006023. https://doi.org/10.1161/CIRCINTERVENTIONS.117.006023
Gaur S, Taylor CA, Jensen JM, Bøtker HE, Christiansen EH, Kaltoft AK, Holm NR, Leipsic J, Zarins CK, Achenbach S, Khem S, Wilk A, Bezerra HG, Lassen JF, Nørgaard BL (2017) FFR derived from coronary CT angiography in nonculprit lesions of patients with recent STEMI. JACC Cardiovasc Imaging 10(4):424–433. https://doi.org/10.1016/j.jcmg.2016.05.019
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Ron Waksman, MD: Consultant: Abbott Vascular, Amgen, Biosensors International, Biotronik, Boston Scientific, Corindus, Lifetech Medical, Medtronic, Philips Volcano, Pi-Cardia LTD; Advisory Board: Abbott Vascular, Amgen, Boston Scientific, Medtronic, Philips Volcano, Pi-Cardia LTD; Speakers Bureau: AstraZeneca, Chiesi; Grant Support: Abbott Vascular, AstraZeneca, Biosensors International, Biotronik, Boston Scientific, Chiesi, Edwards Lifesciences; Investor: MedAlliance.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hideo-Kajita, A., Garcia-Garcia, H.M., Kuku, K.O. et al. Clinical outcomes of complete revascularization using either angiography-guided or fractional flow reserve-guided drug-eluting stent implantation in non-culprit vessels in ST elevation myocardial infarction patients: insights from a study based on a systematic review and meta-analysis. Int J Cardiovasc Imaging 34, 1349–1364 (2018). https://doi.org/10.1007/s10554-018-1362-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10554-018-1362-9